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Currently, a needle-free approach for diabetics to monitor glucose levels in the interstitial fluid (ISF) is not 
available.  Here we report a path-selective, non-invasive, transdermal glucose monitoring system based on 
a miniaturised pixel array platform (realized either by graphene-based thin film technology, or screen-
printing). The system samples glucose from the interstitial fluid via electro-osmotic extraction through 
individual, privileged, follicular pathways in the skin, accessible via the pixels of the array. Proof-of-principle 
using mammalian skin ex-vivo is demonstrated of specific and “quantized” glucose extraction/detection via 
follicular pathways, and across the hypo- to hyper-glycaemic range in humans. Furthermore, the 
quantification of follicular vs non-follicular glucose extraction fluxes is clearly shown. In vivo continuous 
monitoring of ISF-borne glucose with the pixel array was able to track blood sugar in healthy human 
subjects. This novel approach paves the way to clinically relevant glucose detection in diabetics without 
the need for invasive, “finger-stick” blood sampling.  
The World Health Organization predicts the world-wide incidence of diabetes to increase from 171M in 2000 to 366M 
in 20301. An essential feature of diabetic care is the frequent monitoring of blood glucose, conventionally via an 
invasive “finger-stick” procedure. This approach, however, suffers from significant user resistance, primarily due to 
pain and discomfort. The relatively recent development of implantable and microneedle-based temporary sensors2-
4 which are particularly important for very brittle Type 1 diabetics, is not a suitable or economically viable solution for 
the much larger (and rapidly growing) number of Type 2 sufferers of the disease5. Non-invasive methods have been 
proposed involving, for example, detection of glucose in sweat6-8 or tears9,10 or saliva11 but these strategies have two 
limitations: (a) significant variability in the level of glucose detected, and (b) the unknown proportionality between 
the measured glucose concentration in these fluids to that in the blood. Inevitably, therefore, calibration via a “finger-
stick” is required. Impedance and spectroscopic (e.g., infrared) techniques have also been examined12-14 but, in 
addition to the calibration challenge, these methods suffer from interference and a consequent lack of specificity.  
The only technology to offer non-invasive, continuous glucose monitoring used reverse iontophoresis (RI) to extract 
interstitial fluid (ISF) though the skin via electro-osmosis15. This approach was embodied in the GlucoWatch 
Biographer®16,17, which received U.S. Food & Drug Administration approval in 2001. In this method, a small electric 
field is applied across the skin causing ion flow to occur. Because, under normal physiological conditions, the skin 
is net negatively charged, there is an electroosmotic flow of ISF from within the skin towards the cathode on the skin 
surface18,  where glucose is detected and quantified. The GlucoWatch® exploited the known correlation between ISF 
and blood glucose concentrations19,20 (and the inter-individual consistency of the overlap between glucose levels in 
the ISF and capillary and venous blood levels during rapid changes in glycaemia21-23) to provide essentially 
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continuous monitoring of blood sugar for up to 12 hours. However, a “finger-stick” calibration remained a requirement 
primarily because glucose was extracted indiscriminately and variably across a relatively large area of skin (>3 cm2) 
and underwent substantial dilution before quantification. Therefore, the device did not exploit the fact that most of 
the electroosmotic flow during iontophoresis follows low resistance, preferential pathways associated primarily with 
hair follicles24-26. This is the basis for the concept proposed and tested here (Figure 1(a)): to create a device with an 
array of miniature ‘pixels’, into some of which the ISF drawn through the skin electro-osmotically is captured into a 
known, small volume permitting the calibration-free detection of systemic glucose concentration. This is achieved by 
fixing the pixel’s area and volume so that the dilution factor of the extracted glucose is constant and independent of 
follicular density (Supplementary, Figure S1). Given the range of hair densities in humans on conveniently accessible 
sites on the body (e.g., 18 to 36 hairs/cm2 on the arms, thorax, thighs27), a correctly chosen array ensures that the 
majority of individual pixels interrogate a single preferred pathway, that a redundancy of these pathways can be 
interrogated (Figure 1(b), and Supplementary, Figure S2), and that the variability in detection seen with the 
GlucoWatch® (and a more recent “tattoo”-type version thereof28) can be avoided and the “finger-stick” calibration 
requirement relaxed.  
Path-selective glucose monitoring platform: concept 
A miniature, individual pixel of such an array, embodying/achieving this principle comprises (Figure 2 (a)): (i) a 
glucose oxidase-bearing hydrogel reservoir, into which glucose is extracted transdermally, (ii) an electrochemical 
glucose sensor, specifically a graphene-based film decorated with platinum nanoparticles for enhanced sensitivity, 
and (iii) miniaturized electrodes suitable for sensor electrochemistry and reverse iontophoresis, all supported by a 
flexible substrate. The first-generation prototype we produced relied on thin film technology, including chemical 
vapour deposition (CVD) graphene incorporated in a Pt nanoparticle-graphene hybrid material. Graphene is the 
preferred material because of its mechanical resilience, high conductivity and low capacitive background29, large 
surface area, suitability for patterning and device integration via standard microfabrication techniques30, 
environmental sustainability, and anticipated low cost30,31 (relative to the use of noble metals) in a commercial 
product.  A second-generation prototype used commercially-available screen printing and ink-based (including a 
graphene ink) electrodes. Glucose extracted by reverse iontophoresis reacts with glucose oxidase producing 
hydrogen peroxide, which is detected by the electrochemical sensor. Crucially, the active area of the pixel device 
(into which glucose is extracted) enables access to a single follicular pathway. Assuming an average follicular density 
of 27 follicles per cm2 (at the sites mentioned above27), an active area of 2-6 mm2 maximises the probability of hitting 
a single follicle in a randomly-positioned, untargeted measurement (Figure 1(b), panel 1). A 4 x 4 array of pixels 
guarantees at least one follicular “hit”, while larger arrays ensure useful redundancy (Figure 1(b), panels 1 and 2, 
and Supplementary, Figures S2 and S3).  Further, restricting the pixel active area to 2-5 mm2 ensures the dominance 
of single follicular hits per pixel across the follicular density range of 18 to 36 hairs/cm2 (Figure 1(b), panel 2, and 
Supplementary, Figures S2 and S3). The gel volume in a pixel additionally determines the extent of dilution of the 
extracted glucose, and hence the concentration range over which the sensor operates.  
To provide proof-of-principle, we first tested a deconstructed individual pixel device (Figure 2(b)), where a detachable 
gel reservoir was placed on top of excised porcine skin (an excellent model for the human skin barrier32,33) and into 
which glucose was extracted. Subsequently, the reservoir was transferred onto a Pt nanoparticle-decorated 
graphene electrode for glucose detection. Both extraction and detection circuits were completed by miniaturized 
wire electrodes to provide a more customary, three-dimensional geometry for benchmarking measurements. In this 
way, dual glucose extraction-detection through single follicular pathways using miniature pixel geometries was 
demonstrated, and both follicular and non-follicular glucose extraction fluxes were quantified. Second, a 2 x 2 pixel 
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array was created with all elements integrated on a flexible substrate (Figure 2(c)) following the concept design and 
geometric requirements outlined above, and the pixels’ performance was compared with that obtained with the three-
dimensional geometry. A first-generation prototype, based on thin film technology and CVD graphene, demonstrated 
all functional aspects of the array. In particular, ex-vivo, porcine skin-based experiments enabled direct visualisation 
of the follicular pathways probed and, using specific subdermal glucose concentrations, showed that the glucose 
detection current (the output of an extraction-detection cycle) is “quantized”, with a “quantum” corresponding to the 
read-out from a single follicular pathway. Finally, a second-generation prototype 2 x 2 pixel array of similar 
architecture, but based entirely on screen printing (including a graphene ink), was then used to demonstrate the 
concept in-vivo in healthy human subjects. 
Operational characteristics of an individual pixel 
Response to glucose: deconstructed sensor 
Figure 3(a) displays the electrochemical current vs glucose concentration calibration curve of a 3 x 3 mm2 Pt 
nanoparticle-decorated CVD graphene sensor measured with the three-dimensional set-up in Figure 2(b), panel 2.  
In this experiment, glucose was presented to the sensor in a 24 L enzyme-encasing gel reservoir. Data were 
obtained from the sensor’s chronoamperometric response, at an operational potential of 0.4 V, to a wide range of 
concentrations, from sub-micromolar to more than millimolar (Supplementary, Figure S6). A sensitivity of ~2.2 µA 
mM-1 cm-2 was determined, with a limit of detection (LoD) of 2.8 M (Methods).  
For specific RI extraction conditions (i.e., extraction current, current density and time of 0.2 mA, ~ 2.2 mA/cm2 and 
1 hour, respectively), the hypo- to hyper-glycaemic range in diabetics (3.5-12 mM in the blood34), after dilution within 
the reservoir gel volume, maps completely onto the sensor calibration curve (Figure 3(a)). The corresponding 
glucose concentration range in the gel was 8-25 M (Methods), well above the sensor’s LoD. Clearly, a significant 
decrease in reservoir volume (e.g., to the L range), while maintaining the same operational concentration range, 
proportionally decreases the glucose extraction current and time. This informed the further design and operational 
parameters of the individual pixel devices within the planar array. 
Follicular vs non-follicular glucose extraction fluxes 
The preferential RI extraction of glucose through hair follicles was first established in two experiments using the 
deconstructed configuration (Figure 2(b)): first, via hair “targeting”, where the miniature gel “pixel” was positioned 
directly on a single hair follicle and, second, by comparing extraction across skin samples with varying amounts of 
hair. In both experiments, RI was conducted under the same conditions on two skin samples with different follicular 
densities; identical gel reservoir volumes (24 L) were used and the electrochemical detection of glucose therein 
was performed with the same graphene sensor. This approach employed the experimental configuration in Figure 
2(b), with the gel “pixel” not yet permanently integrated with the graphene sensor. Single-follicle, “hair-targeted”, 
preferential extraction on a skin sample with 34 hairs/cm2 was compared with that from another that was relatively 
devoid of follicles (6 hairs/cm2), and the relative RI extraction fluxes via follicular and non-follicular pathways were 
estimated. For this, the chronoamperometric curves obtained after glucose extraction are used to determine an 
average detection current (Figure 3(b), panel 1) which, when interpolated on the current-concentration calibration 
curve of the sensor, provides the extracted glucose concentration within the pixel gel (Figure 3(b), panel 2) and 
hence the glucose extraction flux (Methods).  
At a subdermal concentration of 10 mM, glucose flux via the preferential pathways was 3.5 nmol mA-1 hr-1, compared 
to that across non-follicular skin of 0.4 nmol mA-1 hr-1.  These values are consistent with the glucose extraction flux 
(4.5 nmol mA-1 hr-1) across porcine skin ex vivo calculated from large area extraction experiments reported earlier24.  
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More importantly, they agree with data from the planar pixel arrays developed next (Figures 4 and 5). The preferential 
pathway result also concurs with direct observations of enhanced follicular electro-transport of hydroquinone and 
the independent quantification of electro-osmosis using scanning electrochemical microscopy26. The research 
described here, however, represents the first direct demonstration of extraction and quantitative detection at a single 
follicle level using a technology platform compatible with the construction of a fully integrated glucose monitor.  
The electrochemical detection of glucose described above was independently validated by quantitative 1H-nuclear 
magnetic resonance (1H-qNMR)35 (Supplementary, Figure S8 and Tables S1-S2).  
A 2 x 2 pixel array on a flexible substrate  
Figure 4 compiles representative ex-vivo extraction-detection experiments with three different 2 x 2 thin film/ CVD 
graphene-based arrays as described above, and compatible with a final implementation (Figures 4(a) and 1(b)). The 
volume of the pixel gel reservoirs was significantly reduced to 1- 2 L enabling the array’s operational parameters 
to be appropriate for realistic usage: e.g., 5-minute periods of extraction, at a current density of ~ 0.5 mA/cm2. The 
outcome is an operational range (Methods) for the glucose concentration in the pixel gel indicated by the purple area 
in Figure 4(c), panel 1. With an increased density of graphene-decorating Pt nanoparticles, the detection current 
normalised to the macroscopic area of the sensing electrode is more than an order of magnitude greater than that 
for the deconstructed, three-dimensional pixel device (Supplementary, Figure S14): that is, the sensitivity increases 
to 37 A mM-1 cm-2, while the LoD is improved to about 0.76 M (Figure 4(b), panel 1). Viability of the array design 
was also demonstrated using gold (a more conventional sensing material) and resulted in very similar calibration 
curves to CVD graphene when integrated in an identical array design (compare Figure 4(c), panel 1 with Figure S15, 
Supplementary).  
As detailed below, the Pt nanoparticle - CVD graphene array demonstrated all the required functional aspects: (i) 
lack of response to interfering species in real-life conditions (Figure 4(b), panel 2, and Supplementary, Figure S12), 
(ii) targeted extraction (Figures 4 (c-d)), (iii) correlation and proportionality with the number of hair follicles probed by 
the respective pixels (Figures 4 (c-d)), (iv) capability to detect glucose extracted through a single hair follicle (Figure 
4(d)), (v) proportionality with the concentration of subdermal glucose (Figure 4(c), panel 3; see also Figure 5(a)), 
and (vi) close operational characteristics of pixels both within an array and between different arrays (Figures 4(c), 
panel 1 and Supplementary, Figure S10).  
A number of potential interfering species can be found in the ISF, such as acetaminophen and ascorbic acid (up to 
0.1 mM36,37) and uric acid (up to 0.25 mM38). Uric and ascorbic acids are negatively charged and are therefore 
extracted to the anode, i.e., the opposite electrode to that where glucose is found (electro-osmotic flow across the 
net negatively-charged skin carrying neutral compounds to the cathode, of course - Figure 2(b), panel 1). Only 
acetaminophen (also uncharged), therefore, is a potential interfering species for glucose. Supplementary, Figures 
S12, and S13 demonstrate the lack of response of the array sensor to all of these species. 
For glucose extraction, the reverse iontophoresis extraction circuit employs the largest of the Ag/AgCl electrodes 
(labelled 1 on Figure 4(a)), located on two adjacent pixel devices, as the anode and cathode. In this configuration, 
during half of the operation cycle, glucose is extracted into one of the pixels while, in the second half, the direction 
of the extraction current is reversed, and glucose is extracted in the other pixel. In this way, the AgCl content of the 
extraction electrodes remains essentially constant (Methods).  
Figure 4(c), panel 2 shows the set of chronoamperometric detection curves obtained after extraction via each of the 
pixels of an array (for which sensitivity calibration curves are in Figure 4(c), panel 1); each pixel probed a certain 
number of follicular pathways, determined by visual inspection. Each of these chronoamperometric curves was 
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analysed in a manner similar to that utilized in Figure 3(b): the time-averaged read-out current between 50 and 600 
seconds was used with the current-concentration calibration curve of the respective pixel (from Figure 4(c), panel 1) 
to obtain, by interpolation, the concentration of glucose extracted within the pixel. The glucose concentration thus 
determined is “quantized”, i.e., proportional to the number of follicles probed by each pixel. To simply convey this 
result, the inset of Figure 4(c), panel 2, relates the four read-out average currents of the array to these quantized 
concentration values via the average of the four calibration curves from panel 2 (instead of showing, for each pixel, 
its individual calibration curve, as used in the actual analysis). Figure 4(d) shows chronoamperometric detection 
curves, correlated with images of the hair follicles targeted by the pixels of an array, to show how the extraction-
detection is practically performed. In this case, detection after extraction through a single follicle could also be 
probed, corresponding to the “quantum” of extracted glucose concentration. Measuring all pixel devices across all 
three arrays in Figure 4 yielded “quanta” of 18.9  2.1 M glucose in the pixel gel and 8.97  1.01 nA read-out 
current per follicle, for a 5-minute period of extraction into a 1 L gel, at 0.5 mA/cm2 RI current density, and with 10 
mM glucose subdermally. This is consistent with a glucose follicular extraction flux of 4.6  0.5 nmol mA-1 hr-1, a 
value slightly higher than that determined with the deconstructed pixel and possibly attributable to the different two- 
and three-dimensional geometries used. Furthermore, extraction via non-follicular skin in similar conditions results 
in a detected current that decays much faster than that observed after follicular extraction (Figure 4(c), panel 2), due 
to the very low glucose content within the pixel gel. Taken together, these experiments unequivocally demonstrate 
that the array operates as designed, by exploiting the hair follicles as the preferential transdermal extraction paths 
for glucose. In addition, Figure 4(c), panel 3 shows that, after extraction to the same pixel device under identical 
conditions, the detected current is proportional to the subdermal glucose concentration (10 and 100 mM were used 
here; see also Figure 5(a)).  
In-vivo monitoring with a 2x2 screen printed array 
In preparation for in-vivo experiments, similar ex-vivo measurements were extended to a prototype, second-
generation, screen-printed array, based on the same architecture as the thin-film/CVD graphene-based arrays 
above. The CVD graphene working electrodes of the first-generation arrays were replaced with graphene ink-based 
electrodes, decorated with Pt nanoparticles. The first and second generation prototypes have close operational 
characteristics as shown, for example, by their calibration (Supplementary, Figure S14) and chronoamperometric 
curves (Figures 4 and 5(a)). The screen-printed arrays are expected to sustain more extraction/detection cycles 
(suitable for continuous in-vivo use) than those based on thin films due to the 6-fold increase in Ag/AgCl electrode 
thickness (Methods). 
The read-out current of screen-printed pixel devices in ex-vivo experiments (determined from the 
chronoamperometric curves by averaging, as above) was proportional to the subdermal glucose concentration 
across the entire hypo- to hyper-glycaemic range (Figure 5(a), panels 1 and 2); and a plot (Figure 5(a), panel 3) of 
read-out current as a function of expected values of in-gel extracted concentration (C1* to C4*, as calculated using 
the same extraction/detection conditions as for the CVD graphene-based arrays, the follicular flux determined from 
Figure 4, and the four subdermal concentrations used for extraction) maps very well onto the calibration curve of the 
device. A conversion factor F (characteristic of the current pixel device architecture and extraction conditions, see 
Methods) from the subdermal glucose concentration to that in 1 L of pixel gel, and per follicular pathway, of the 
order of 2.4 x 10-3 was then determined.  
Finally, in-vivo testing was performed on two healthy volunteers, and representative results are in Figure 5(b). Panel 
1 shows the wired array strapped to the volunteer’s forearm (see also Supplementary, Figure S17). Glucose was 
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monitored over 6 hours, during which “lunch” and a “snack” were ingested (Figure 5(b), panel 3). The blood glucose 
was tracked using a commercial glucose meter (Accu-Chek® Mobile). In parallel, RI-extracted ISF-borne glucose 
was monitored by two of the array’s pixel devices working in tandem (see Methods and above), and produced well-
matched read-out values that provided further confidence in the performance of the array. The ISF glucose profile 
closely follows that of blood glucose, with a lag of about 15 minutes, as expected19,39. Importantly, control 
experiments show that, without RI, no glucose was detected (Supplementary, Figure S16), confirming that, under 
normal transdermal monitoring conditions, i.e., when the user is not actively perspiring (e.g., due to strenuous 
exercise or high ambient temperatures), there is no contamination of the ISF-borne glucose by that in the sweat. 
Nonetheless, it is essential that future development of the approach described characterises, in comprehensive 
clinical experiments, the response of the device to the full range of hypo- to hyper-glycaemia in diabetics, as well as 
that, for example, in individuals undertaking physical activity or exposed to rapid changes in environmental conditions 
(such as leaving an air-conditioned office into a high humidity and temperature outside).   
Conclusions 
Proof-of-concept is demonstrated for non-invasive, transdermal, path-selective and specific glucose monitoring, 
based on an array of miniature pixel devices integrated on a flexible substrate. In this way, interstitial fluid-borne 
glucose via individual, privileged follicular pathways across the skin is extracted and detected, producing “quantized” 
read-outs of subdermal glucose. The concept is founded on the array architecture rather than the specific sensor 
implementation. Pixel arrays (2 x 2) on mammalian skin ex-vivo enabled the evaluation and demonstration of all 
critical parameters and functional aspects of the monitor, and future work focuses on extending the array size to at 
least 4 x 4 (to ensure random sampling of single follicles). In-vivo testing on healthy human subjects demonstrated 
the ability to continuously track blood sugar for 6 hours, and extending this operation time is an ongoing objective. 
Graphene-supported platforms (e.g., incorporating CVD graphene, or graphene inks via screen printing, as shown 
here) are preferred implementations for cheap, flexible, high-throughput and green arrays. Unlike other “wearable” 
approaches for glucose monitoring, the technology described here should ensure that the relationship between 
measurements made by the device and the actual blood glucose concentrations is not subject to inter- and intra-
individual fluctuations in skin characteristics. This achievement should pave the way to calibration-free non-invasive 
glucose monitoring. 
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Figure captions 
Figure 1. Principle of a pixel-based array targeting transdermal individual preferential glucose pathways. (a) 
Preferential glucose pathways (i.e., hair follicles) are targeted by individual, miniature pixel extraction-detection 
devices. With a sufficiently dense pixel array and the correct pixel size, a number of such pathways are sampled 
randomly and individually by the pixel devices. In this way, the concentration of glucose extracted via the hair follicles 
is in a fixed relationship to that in the interstitial fluid (ISF). (b) Panel 1: Probability P that the array has at least one 
working pixel with just a single pathway per pixel (calculated at 27 follicles/cm2; i.e. the median value across a typical 
follicular density range at easily accessible skin sites in humans), as a function of pixel active area and for various 
numbers of pixels in the array.  Here, the active area is defined as the pixel device area through which glucose 
extraction takes place, coinciding with the footprint area of the gel reservoir (see Figures 2 (a), (c)). Panel 2: 
Probability P as a function of pixel active area for a 4  4 array for three selected follicle densities spanning the 
follicular density over a wide range of suitable sites, e.g. arm, back and thigh. A common range of pixel areas exists 
that guarantees interrogation of individual follicular pathways at these convenient body regions. 
Figure 2. Individual pixel and array concept; extraction-detection operation cycle. (a) Generic individual 
miniature pixel: electrodes 1 (Ag/AgCl) and 4 (Ag) perform glucose extraction; electrodes 1 (Ag/AgCl, reference), 2 
(Pt nanoparticle-decorated graphene, working electrode), and 3 (Pt, counter electrode) detect glucose 
electrochemically. Pt nanoparticles on graphene boost the detection signal. Electrodes 1, 2 and 3 contact a 
miniaturized enzyme-encasing gel reservoir, into which glucose is extracted, and the area of which defines the pixel 
active area. The gel reservoir is formed inside the holes of a supporting elastomer membrane. (b) Deconstructed, 
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three-dimensional pixel configuration. Panel 1: Glucose extraction by reverse iontophoresis (RI). Excised porcine 
skin separates the two halves of a Franz diffusion cell, with the epidermal side facing the upper compartment; the 
lower, sub-dermal compartment contains glucose in phosphate-buffered saline (PBS), and hosts a silver anode. The 
enzyme-containing gel reservoir is positioned on the skin surface, with the Ag/AgCl cathode contacting the gel. As 
mammalian skin carries a net negative charge at pH 7.4, iontophoresis (red arrow) induces electro-osmosis, and the 
transport of glucose (G) in the direction of cation migration. Panel 2: Glucose sensing. After extraction, the gel is 
placed on top of the pixel-sized graphene sensor, and a three-dimensional electrochemical cell is formed by 
contacting the gel with Ag/AgCl (reference) and Pt (counter) electrodes. (c) Planar 2  2 array, on a flexible substrate, 
performing non-invasive glucose extraction-detection ex vivo (on porcine skin). For simplicity, both electrodes 1 and 
3 (reference, in detection) are Ag/AgCl, conferring increased chemical stability after repeated extraction-detection 
cycles (see Methods). Extraction occurs within pixel a via electrodes 1 (cathode) of pixel a and 1’ (anode) of pixel b. 
Next cycle, cathode and anode roles are reversed, extraction occurring in pixel b; thus, AgCl is periodically recycled. 
During detection, the counter electrode is 1.  
Figure 3. Deconstructed pixel device. (a) Calibration curve for a typical Pt nanoparticle-decorated, CVD 
graphene-based electrochemical glucose sensor, 3 x 3 mm2, with Ag/AgCl and Pt wires as external electrodes 
(Figure 2(b), panel 2). Glucose is dispensed into the 24 L enzyme-containing reservoir, H2O2 produced by the 
glucose reaction with the glucose oxidase being detected in the chronoamperometric current recorded at 0.4 V 
applied to the graphene electrode against the micro Ag/AgCl reference. The hypo- to hyper-glycaemic range, after 
dilution in the pixel gel, maps as indicated in purple (see Methods). (b) Glucose extraction-detection; 
determination of follicular vs non-follicular glucose extraction fluxes. Glucose was extracted for 1 hour via the 
configuration in Figure 2(b), panel 1, at an iontophoretic current of 0.2 mA (corresponding to a current density of 2.2 
mA/cm2), and with 100 mM subdermal glucose, through (i) a single hair follicle (using a skin sample with 32 
hairs/cm2), and (ii) non-follicular skin (using a skin sample with only 6 hairs/cm2), into two separate 24 L enzyme-
containing gel reservoirs. Panel 1: These samples were then measured by chronoamperometry by the same 
graphene-based sensor using the configuration from Figure 2(b), panel 2. Chronoamperometric current baselines 
were also recorded before RI in both cases. Panel 2: After subtraction of the respective baselines, average values 
of the detected current, I1 and I2, were determined over the 50 to 600 s range, respectively. Then, in reference to the 
detection current-concentration calibration curve of the sensor, the concentrations of glucose C1 and C2 for the two 
cases were determined by interpolation (see also Methods). Subsequently, these values, reflecting the concentration 
of extracted glucose after dilution in the volume of the pixel gel, were used to calculate follicular and non-follicular 
extraction fluxes (Methods). 
Figure 4. A functional, fully integrated, CVD graphene-based 2 x 2 pixel array on a flexible substrate. (a) 
Array realization. Panel 1: Complete layout, comprising electrodes for extraction-detection, sensing regions (Pt 
nanoparticle-decorated graphene of 2 mm2 each), and an elastomer membrane with perforations (panel 2) within 
which a glucose oxidase-encasing hydrogel was deployed forming extraction regions of about 6 mm2 each (dashed 
contours, panel 3). Electrodes 1 to 3 participate in extraction-detection (4, unused). (b) Panel 1: Linear response 
(Methods) of pixel sensor to 0.006 to 0.7 mM glucose. Panel 2: Response to glucose (red), PBS (cyan), 
acetaminophen (teal) and ascorbic acid (purple) for in-gel concentrations shown in inset (see also Supplementary, 
Figure S12). (c) 10 mM subdermal glucose was extracted across porcine skin ex vivo for 5 minutes under ~0.5 
mA/cm2 RI current. Panel 1: Sensitivity calibration curves (raw chronoamperometry data in Supplementary, Figure 
S9) for the 4 pixel devices, demonstrating very similar current-concentration dependencies. Targeted concentration 
operational range (Methods), in purple. Panel 2: Detected current versus time after glucose extraction within each 
of the four pixels characterized in panel 1; number of follicles targeted by each of the pixels is indicated; PBS 
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extraction used as a negative control (black baseline). Inset: averaged detected current correlated with in-gel glucose 
concentrations. Panel 3: Detected current versus time after extractions using the same pixel device for 10 and 100 
mM subdermal glucose concentrations, respectively. Extracted, in-gel glucose concentrations agree with 
calculations based on the follicular extraction flux and the number of follicles probed (Methods; Supplementary, 
Figure S11). (d) An example of visual correlation between number of follicles probed by each array pixel (6mm2 
extraction area, dashed contour, over skin with ~28 follicles/cm2), panel 1, and current detected after extraction of 
10 mM subdermal glucose, panel 2. Array electrodes are visible through the skin.  
Figure 5. Second generation, screen printed, 2x2 array. (a) Ex-vivo (porcine skin) testing over the hypo-to-
hyper glycaemic range. Panel 1: Chronoamperometric detection curves after 5 minutes of extraction at 0.5 mA/cm2 
current density across 6 mm2 extraction area, and subdermal glucose concentrations spanning the hypo-to-hyper 
glycaemic range; extraction through 2 hair follicles into ~2 L of gel (equivalent to 1 hair follicle per 1 L gel). Panel 
2: Proportionality of the read-out current (i.e., the detection current averaged over the 50 to 600 s range) to the 
subdermal concentration. Panel 3: The read-out current maps onto the linear calibration curve, yielding “in-gel” 
glucose concentrations C1* to C4* in agreement with the follicular extraction flux determined from Figure 4. (b) In-
vivo continuous glucose monitoring on healthy human subjects. Panel 1: Screen printed array fixed onto 
volunteer’s forearm, and connected to a potentiostat. Array layout and components same as in Figure 4(a), panel 1; 
additionally, an electrically insulating layer (green) covers all interconnects, underlying the perforated elastomer 
membrane aligned on top of it. Panel 2: Example of chronoamperometric detection curves (corresponding to various 
blood glucose concentrations), acquired during alternating 5 minutes periods of extraction-detection (Methods); 
shorter detection times than used in Figure 4 enabled good tracking of the blood glucose profile shown in Panel 3. 
Panel 3: Two pixels (a and b) worked in tandem (ensuring periodic AgCl recycling in each pixel (Methods)), 
alternatingly delivering read-out values of ISF-borne glucose. For each pixel, a larger RI current density (1 mA/cm2) 
was used to extract glucose through 2 follicles into ~3 L gel (the larger extraction current compensates for the 
larger pixel gel volume; compare with our benchmarking parameters of 1 follicle per L of gel and 0.5 mA/cm2 
extraction current density), see Figure S17(a). Finger-stick measurements of blood glucose were taken before each 
extraction. 
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Methods 
1. Materials and device fabrication.  
Planar thin film/CVD graphene array.  
CVD Graphene wet transfer onto a polyethylene terephthalate (PET) sheet. CVD-synthesized graphene, grown on 
a copper substrate, was transferred onto a flexible, previously polished PET sheet using a standard wet transfer 
procedure40. For a 2 x 2 array, four such graphene patches (larger than the final, desired size) were placed on the 
PET sheet roughly in the desired locations using a stencil mask (designed for subsequent electrode and track 
definition) to guide alignment. The graphene patches provide the working electrodes for each of the pixels of the 
array in the electrochemical detection of glucose. To prevent potential structural discontinuities/tearing in the 
graphene layer (occurring either during CVD growth or as the result of mechanical stress during the transfer 
procedure) leading to electrical discontinuity, a second graphene layer was subsequently transferred on top of each 
of the original patches.  
Electrode and track deposition through physical vapour deposition (thermal and e-beam evaporation). To deposit 
thin film electrodes with a defined geometry, sets of polyimide industrial tape (Kapton®), laser-machined stencil 
masks were placed successively and aligned on top of the PET-supported graphene patches. The stencil mask sets 
were tailored to the array layout. To complete the reference/counter Ag/AgCl electrodes, a 500 nm silver film was 
deposited on top of a 20 nm palladium layer previously deposited to promote adhesion of the silver layer, followed 
by a 500 nm thick AgCl layer. Such thick layers of Ag and AgCl are needed to ensure a long lifetime of the reference 
electrode41.  
Choice of materials for extraction and electrochemistry electrodes. Extraction: Ag/AgCl has been chosen as the 
material for the extraction electrode couple due to the ability of AgCl to recover its surface chemical composition 
after electrochemical stress, hence ensuring its stability after repeated cycles of extraction-recovery that require the 
electrode polarity to alternate. It was found that after four extraction-detection cycles performed with the array, the 
potential across the Ag/AgCl electrodes changed negligibly (by only ~30 mV), establishing their recovery. Detection: 
One of the extraction electrodes was then used as the counter electrode instead of Pt. In this way, the number of 
steps required for the array fabrication was greatly reduced, while not affecting electrochemical detection. Use of 
Ag/AgCl as a pseudo-reference is well-documented28,42; here, its stability was verified in potentiometric experiments 
relative to a standard saturated calomel electrode (SCE). 
Graphene patterning. The graphene patches defining the sensing areas were then patterned in the pre-defined 
geometry (e.g., into 1 x 2 mm2 areas according to the layouts in Figure 4). Although low energy oxygen plasma can 
be used to etch graphene supported by plastic substrates, mechanical cutting (using a scalpel) was successfully 
employed in the current realization to remove the excess graphene from the pixel patches.    
Realization and transfer of an elastomer membrane designed to support the enzyme-encasing gel. 
Polydimethylsiloxane (PDMS) mixed with a curing agent was spin-coated on a PET support sheet and cured, leading 
to a ~100 μm thick membrane. Circular holes (1.5 - 3 mm diameter) or rectangles (~2 x 3 mm2) of similar area were 
then cut to create sockets for the reservoir gel. After careful underwater peeling in a de-ionized water bath, the 
PDMS membranes were transferred onto the array with defined electrodes and tracks, ensuring alignment of the 
sockets to the electrochemical cell region of each pixel. The assembly was then left to dry in air. 
Platinum nanoparticle deposition onto the graphene pixel electrodes. Pt nanoparticles were formed and deposited 
on the graphene sensing regions of the pixels through appropriate stencil masks by DC sputtering under argon. 
Contrary to electrodeposition, sputtering is a method that allows easy scale-up of Pt nanoparticle deposition. By 
tuning the argon gas pressure and sputtering time, particles with 4.5 nm mean diameter were produced. See 
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Supplementary, section 3, and Figure S4 for further characterization of this Pt nanoparticle-CVD graphene hybrid 
material.  
Gel casting and enzyme entrapping (Figure 4). 1 mL of a clear 2% w/v solution of agarose in phosphate-buffered 
saline (PBS) at pH 7.4 was formed by warming above 80˚C and was then cast on a glass slide (allowing it to spread 
and flatten). The gel was left to shrink under accelerated drying in a fume hood for 10 minutes, after which blocks of 
gel (of ca. 1-2 L, determined by weighing), with footprint areas corresponding to predetermined pixel regions, were 
excised. Then, 0.5 to 1 L of enzyme (12 mg/mL) was placed on and absorbed into the electrode side of the gel 
blocks. Finally, the gel blocks were positioned on top of the individual pixels, inside the sockets of the PDMS 
membrane, and glucose subsequently extracted into them. Once in contact with the skin (and sandwiched between 
the skin and the surface of the device), the gel did not shrink any more over the duration of extraction and detection 
experiments presented in Figure 4; this was confirmed by peeling and weighing the gel at the end of the experiment.  
 
Screen printed array 
Realization and characteristics. Screen printed arrays (Figure 5(b), panel 1) were commissioned commercially with 
the same architecture as in Figure 4(a), using an Ag/AgCl ink (DuPont 5874), and a graphene-based ink (HDPlas® 
Graphene Ink IGSC02002 from Haydale Ltd., UK). The process allowed the thickness of the Ag/AgCl electrodes to 
be increased to ~ 6 m, with the aim of increasing the stability and lifetime of the pixel devices. A biocompatible, 
electrically insulating layer (~1 m thick) was also printed around the active areas of the pixel devices, covering the 
conductive tracks of the array. Pt nanoparticles were deposited, using stencil masks, in similar conditions as 
described for the thin film/CVD graphene arrays. A PDMS layer, as described above, was then aligned with the 
active areas of the devices, and the array was completed by placing gel patches on top of the active areas. The gel 
composition was changed (see below), to improve stability (and maintain volume) during long term operation. 
Gel formulation (Figure 5). An agarose-glycerol-water hydrogel was prepared by dispersing agarose (2.5 wt %) 
within an aqueous solution of glycerol (50 wt % in 0.1 M PBS (pH 7.4)). The dispersion was first stirred at 50°C for 
one hour to allow sufficient swelling, then heated at 95 °C for another hour to ensure complete agarose dissolution, 
and finally cooled down to 50 °C prior to pouring it between two glass slides to allow the formation of a thin film. 
Once jellified, the gel was excised using a razor blade according to the pixel dimensions. The addition of glycerol as 
co-solvent increased the stability of the hydrogel by delaying water loss during pixel device operation, and without 
compromising its performance during both extraction and detection.  
This new formulation was used in all the ex-vivo and in-vivo experiments presented in Figure 5. The gel is stable 
(decreasing by ~10 to 15%) when in contact with the skin over ~6 hours of continuous glucose monitoring in-vivo, 
as shown in Figure 5, panel 3; the robust structure of the gel is still evident when the experiment is terminated (see 
Supplementary, Figure S17(b)). Beyond this proof-of-concept, we are pursuing development and optimization of 
more advanced gel formulations.  
2. Calibration of pixel sensors. Interference tests. 
Calibration via glucose additions to the gel. To completely characterise a generic sensor (whether in a deconstructed 
configuration as in Figure 2(b), or in a pixel within an array), a chronoamperometric current versus glucose 
concentration calibration curve was established. In chronoamperometry, the change in the electrochemical current 
with time is tracked at the working electrode, as a function of increasing glucose concentration, at a fixed applied 
potential (here, 0.4V) against an Ag/AgCl electrode. A constant volume of increasingly concentrated glucose 
solutions (in PBS) was successively added, at regular intervals, to the enzyme-containing gel reservoir (raw 
chronoamperometry data in Supplementary, Figures S6 and S9), and the increase in the catalytic current relative to 
the background (i.e., in the absence of glucose) was determined; an average of 10 readings in the plateau region of 
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the current step were recorded for this purpose. For the pixel array devices, delivery on top of the counter electrode 
mimics the glucose path during actual extraction conditions (see description of extraction circuit in Figure 2(c)), while 
at the same time allowing the system to stabilize after each glucose addition. Reservoirs larger than 3 L are 
preferable to minimise occasional current transients associated with mechanical effects due to manual delivery of 
analytes. All calibration experiments were performed in a glove box in conditions of high humidity to prevent shrinking 
of the gel reservoirs. From five successive, replicate calibration curves obtained with the same device, the standard 
deviation in the data broadly equated to 10 to 12% of the corresponding mean. We attribute this variability to pipetting 
accuracy and to small variations in the original pixel gel volume. We use this error across all the calibration data 
presented in this work. Having established similarity in the response of several batches of devices, for the routine 
characterization of similarly produced sensors, fewer glucose concentrations were used to create the calibration 
curve. 
Correlation between calibration curve and chronoamperometric detection current. We have verified that the 
averaging procedure over the time interval mentioned in the main text of the chronoamperometric detection current 
produces values that match well the calibration curves obtained from step glucose additions to the pixel gel. Figure 
5(a), panels 1 to 3 present an example of such good correlation. 
Interference tests with pixel arrays. Acetaminophen, ascorbic acid, and uric acid were tested as potential interferants 
to glucose detection (though only acetaminophen is expected to be extracted within the pixel reservoirs by reverse 
iontophoresis, see main text). Throughout the experiments on pixel arrays, additions to the gel reservoirs created 
physiologically pertinent interferant-to-glucose ratios; the smallest concentration of interferant delivered to the pixel 
reservoirs was close to the limit of detection of our pixel devices (Supplementary, Figures S12-13). CS, the subdermal 
glucose concentration, corresponding to C, the in-gel concentration, can be determined via the relationship
   ( )1 / 1
S
C C F V L L 
−
=   , where V is the volume of gel reservoir, and F is the “subdermal-to-in-gel” conversion 
factor evaluated for 1 L of gel. For a single follicular path, and extraction conditions used throughout this work for 
the pixel arrays, F was estimated to be about 2.4 x 10-3 (see main text). Further data and related discussion can be 
found in Supplementary (see Figures S12-13). 
3. Limit of detection (LoD), sensitivity, and operational range 
The LoD of a generic sensor (in a deconstructed configuration or in a pixel within an array) was determined from the 
relationship 𝐿𝑜𝐷 = 3.3 ∙ 𝜎 𝑆⁄ 43,44, where  is the standard deviation of the noise (as determined from the raw 
chronoamperometry data from Figures S6 and S9, Supplementary), and S is the slope of the sensor’s linear 
calibration curve (e.g., as determined from Figures 4(b), panel 1, 5(a), panel 3, or Supplementary, Figure S7). 
Sensitivity was defined as the slope of the sensor’s calibration curve (e.g., as shown in Figures 4(b), panel 1, or 
Figure S7 in Supplementary) normalized to the geometrical area of the pixel electrode (i.e., 3 x 3 mm2 for the 
deconstructed pixel device, and 1 x 2 mm2 for electrode 2 in Figure 4(a), panel 1); further relevant discussion can 
be found in Supplementary, section 7. The operational range for the glucose concentration in the pixel gel C can be 
established using the relationship 𝑗 ∙ ∆𝑡 ∙ 𝐼 ∙ 𝑁 = 𝐶 ∙ 𝑉, where j, the glucose extraction flux (see below), scales with 
the subdermal glucose concentration spanning the hypo- to hyper-glycaemic range; N is the number of hair follicles 
through which extraction takes place. The operational range can be adjusted by varying parameters such as t and 
I, the extraction time and current, respectively, as well as V, the volume of the pixel gel (equal to the active 
(extraction) area of the gel multiplied by the thickness of the gel).  
4. Determination of follicular vs non-follicular glucose extraction fluxes.  
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The procedure described in Figure 3(b) allowed C1 and C2, the glucose concentrations within the pixel gel 
corresponding to follicular and non-follicular extraction, respectively, to be determined. Using these values, and the 
relationship 𝑗 ∙ ∆𝑡 ∙ 𝐼 ∙ 𝑁 = 𝐶 ∙ 𝑉, as above, the follicular and non-follicular glucose extraction fluxes were determined. 
The values obtained are proportional to the subdermal glucose concentrations (100 mM in the data from Figure 3), 
and scaling is therefore required when the subdermal concentration changes. The follicular and non-follicular fluxes 
reported in the main text were scaled to 10 mM subdermal glucose concentration. Data from Figure 4 (corresponding 
to the planar thin film/CVD graphene arrays) were used to independently determine a value for the follicular 
extraction flux (see main text). This also allowed one to determine whether the extraction geometry of the planar 
pixel array has an influence over the extraction process.  
5. Extraction-detection cycle with a pixel array.   
Ex-vivo experiments. Fresh abdominal pig skin was dermatomed (Zimmer®, Ohio, USA) to a nominal thickness of 
750 µm and then cut into suitably-sized pieces, before being frozen until used. In contrast to the deconstructed 
device in Figure 2(b) (see also Supplementary, section 4), the anode and cathode now contacted the skin on the 
same side (Figure 2(c)) making the measurement truly non-invasive. The dermatomed pig skin was placed over the 
sensor, with the external side in direct contact with the pixel array, while the subdermal side faced the operator 
allowing the alignment of the gel reservoir regions (i.e., the active areas of the pixel devices) to the clearly visible 
follicles (made possible by the partial transparency of the skin). Buffer-saturated absorbent tissue was used as the 
subdermal compartment in which glucose solution was dispensed. A piece of paraffin film was placed over the 
impregnated tissue and pressure was applied to ensure contact between the skin and the gel reservoirs. We did not 
specifically perform an analysis of behavior under stress but, in the current conditions, the extraction results are 
reproducible and compatible with what is expected from glucose flux estimations. Hence, stress, at least thus far, 
does not negatively affect the operation of the device. 
Glucose was extracted under a current density of ~0.5 mA/cm2 for 5 minutes into the gel reservoir (1-2 μL in volume, 
~6 mm2 in cross section) using an Ag/AgCl electrode couple provided by two adjacent pixels, and detected for 10 
minutes. Once the extraction was completed, glucose detection was performed (procedure described in Figure 3) 
without changing the sensor position. No significant gel volume variation was recorded in these experiments, when 
the gel was sandwiched between the pig skin and the device surface, and laterally confined by the PDMS membrane. 
Cathode and anode of the iontophoresis circuit are provided by two different pixels and alternate from cycle to cycle 
(see Figure 2 (c)). Thus, the “two pixel” extraction-detection cycle follows the following steps: (1) extraction in pixel 
a, accompanied by depletion of AgCl from pixel a electrode (the cathode in the electrochemical reaction); (2) 
detection of extracted glucose by chronoamperometry in pixel a; (3) pixel a gel cleaning: with a high glucose 
subdermal concentration (e.g., 100 mM), two or three chronoamperometry detection cycles are performed to 
completely deplete the extracted glucose from the gel; and (4) glucose extraction in pixel b, accompanied by the 
recovery of the AgCl surface layer of pixel a electrode (now the anode in the electrochemical reaction).  
In-vivo experiments. The protocol (REACH EP 17/18 94) was approved by the University of Bath Research Ethics 
Approval Committee for Health. Healthy, non-diabetic volunteers underwent an overnight fast, and the area of the 
forearm where the sensor would be applied had been carefully shaved and cleaned. The array was strapped onto 
the skin with mild pressure, as shown in Figure 5(b), panel 1. Good contact between the skin and the device is 
indicated by a low resistance during RI extraction. In such conditions, the device works within the expected 
parameters, and in agreement with all the other results in the paper. The sensor was first ‘stabilized’ by performing 
several chronoamperometric detection cycles without RI extraction until the results superimposed. Concurrently, 
blood glucose concentrations were measured via conventional “finger-sticks” at regular intervals (using a commercial 
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glucose meter, Accu-Chek® Mobile). Subsequently, the subject consumed a carbohydrate-rich meal (~200 g of 
pasta), triggering the expected response in blood glucose concentration (i.e., a clearly perceptible increase in 
glycaemia followed by its normalisation in response to insulin secretion) over the next 2 - 2.5 hours.  Then, the 
subject consumed a snack containing ~60 g of sugar and the change in blood glucose was followed as before for a 
further period of about one hour.  During this provocation of changes in blood glucose levels, RI extraction and 
electrochemical detection cycles were performed every 10 minutes (the detection stage having been reduced from 
10 minutes to 5 to permit collection of more frequent data points). Measurements with two pixels, working in tandem, 
were alternated as detailed above. The RI glucose signal versus time profile in Figure 5(b), panel 3, in this case, did 
not use the read-out current averaged over 50 to 600 s (as employed in the rest of the work), but instead employed 
the instant current detected at t = 300 s. This alternative method of displaying the output data from the device clearly 
tracked with fidelity the variation in blood glucose concentration. Notably, both the instant measurement (at t = 300 
s, in this case) and the averaged current correlated similarly with the subdermal concentration, as shown in 
Supplementary, Figure S18. With the current pixel characteristics and dimensions, measurement time sequence, 
and overall monitoring period, we did not observe glucose accumulation in the pixels and the lack of “memory effect” 
is also supported by the ex vivo results in Figure 5(a). After extraction, complete glucose conversion to 
H2O2 is anticipated due to the excess quantity of enzyme in the pixel gel; in addition, with the 15-minute delay 
between each detection step within that pixel (i) there is no concern about analyte diffusion-limitation as the pixel 
size is so small, and (ii) disproportionation of any residual H2O2 (leading to pixel “clearing”) is expected, catalysed 
by the Pt45 and Ag nanoparticles46 (present in the screen printed ink) of the various electrochemical electrodes. No 
perceptible discomfort was perceived by the volunteers during the extraction. Only mild tingling under the extraction 
electrodes was transiently (a few seconds) experienced at the beginning of current passage. Further, no skin 
irritation was observed after the 6-hour in-vivo glucose monitoring experiments reported in Figure 5 (Supplementary, 
Figure S17 (a)).  
 
The data that support the plots within this paper and other findings of this study are available from the corresponding 
author upon reasonable request. 
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